2005至2018年美国大型雇主私人保险成人非胰岛素降糖药总支付与自付费用趋势
研究发现旧类药总支付和自付费用下降,新类药总支付上升而自付费用相对不变,新药使用是总支付增加的主要驱动因素。
要点
- 旧类降糖药(二甲双胍、磺脲类等)总支付和自付费用均下降。
- 新类降糖药(DPP-4i、GLP-1RA、SGLT2i)总支付上升,自付费用相对不变。
- 转向新类降糖药是总支付增加的主要驱动因素。
核心结论
- 2005至2018年间非胰岛素降糖药的平均年支付和自付费用显著增加,新药类的使用是主要驱动因素。
主要发现
- 旧类药总年支付下降:二甲双胍-$271(-53.8%),磺脲类、格列奈类、α-糖苷酶抑制剂和噻唑烷二酮类降幅从-$271至-$2406(-92.2%)不等,自付费用也下降。
- 新类药总年支付上升:DPP-4抑制剂+$2181(88.4%),GLP-1受体激动剂+$3721(77.6%),SGLT2抑制剂+$1374(37.0%),自付费用相对不变。
- 转向新类非胰岛素降糖药是总支付增加的主要驱动因素。
临床怎么用
- 临床选择降糖药时需关注新药类带来的总支付上升,但患者自付费用相对稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate trends in total payment and patients' out-of-pocket (OOP) payments of noninsulin glucose-lowering drugs by class from 2005 to 2018. RESEARCH DESIGN AND METHODS: We analyzed data for 53 million prescriptions from adults aged >18 years with type 2 diabetes under fee-for-service plans from the 2005-2018 IBM MarketScan Commercial Databases. The total payment was measured as the amount that the pharmacy received, and the OOP payment was the sum of copay, coinsurance, and deductible paid by the beneficiaries. We applied a joinpoint regression to evaluate nonlinear trends in cost between 2005 and 2018. We further conducted a decomposition analysis to explore the drivers for total payment change. RESULTS: Total annual payments for older drug classes, including metformin, sulfonylurea, meglitinide, α-glucosidase inhibitors, and thiazolidinedione, declined during 2005-2018, ranging from -$271 (-53.8%) for metformin to -$2,406 (-92.2%) for thiazolidinedione. OOP payments for these drug classes also reduced. In the same period, the total annual payments for the newer drug classes, including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors, increased by $2,181 (88.4%), $3,721 (77.6%), and $1,374 (37.0%), respectively. OOP payment for these newer classes remained relatively unchanged. Our study findings indicate that switching toward the newer classes for noninsulin glucose-lowering drugs was the main driver that explained the total payment increase. CONCLUSIONS: Average annual payments and OOP payment for noninsulin glucose-lowering drugs increased significantly from 2005 to 2018. The uptake of newer drug classes was the main driver.
引用
- Shao H, Laxy M, Benoit SR, et al. Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018. Diabetes Care. 2021. PMID: 33563653. doi:10.2337/dc20-2871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。